

## 1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

### 1.1 Product identifier

**Product name** CEPHALEXIN ANTIBIOTIC TABLETS - 200MG, 600MG & 1000MG  
**Synonym(s)** CEPHALEXIN 1000MG • CEPHALEXIN 200MG • CEPHALEXIN 200MG, 600MG, 1000MG ANTIBIOTIC TABLETS • CEPHALEXIN 600MG

### 1.2 Uses and uses advised against

**Use(s)** ANTIBIOTIC • VETERINARY USE

### 1.3 Details of the supplier of the product

**Supplier name** APEX LABORATORIES PTY LTD  
**Address** 2 Cal Close, Somersby, NSW, 2250, AUSTRALIA  
**Telephone** (02) 4372 1661  
**Fax** (02) 4372 1668  
**Email** [thevet@apexlabs.com.au](mailto:thevet@apexlabs.com.au)  
**Website** <http://www.apexlabs.com.au>

### 1.4 Emergency telephone number(s)

**Emergency** 13 11 26 (Poisons Information Centre)

## 2. HAZARDS IDENTIFICATION

### 2.1 Classification of the substance or mixture

CLASSIFIED AS HAZARDOUS ACCORDING TO SAFE WORK AUSTRALIA CRITERIA

**GHS classification(s)** Skin Sensitisation: Category 1

### 2.2 Label elements

**Signal word** WARNING

**Pictogram(s)**



**Hazard statement(s)**

H317 May cause an allergic skin reaction.

**Prevention statement(s)**

P261 Avoid breathing dust/fume/gas/mist/vapours/spray.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P280 Wear protective gloves/protective clothing/eye protection/face protection.

**Response statement(s)**

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.  
P321 Specific treatment is advised - see first aid instructions.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.  
P363 Wash contaminated clothing before reuse.

**Storage statement(s)**

None allocated.

**PRODUCT NAME CEPHALEXIN ANTIBIOTIC TABLETS - 200MG, 600MG & 1000MG****Disposal statement(s)**

P501 Dispose of contents/container in accordance with relevant regulations.

**2.3 Other hazards**

No information provided.

---

**3. COMPOSITION/ INFORMATION ON INGREDIENTS**

---

**3.1 Substances / Mixtures**

Ingredient	CAS Number	EC Number	Content
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	Remainder
CEPHALEXIN MONOHYDRATE	23325-78-2	-	<70%

---

**4. FIRST AID MEASURES**

---

**4.1 Description of first aid measures**

<b>Eye</b>	If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.
<b>Inhalation</b>	If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
<b>Skin</b>	If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.
<b>Ingestion</b>	For advice, contact a Poisons Information Centre on 13 11 26 (Australia Wide) or a doctor (at once). If swallowed, do not induce vomiting.
<b>First aid facilities</b>	None allocated.

**4.2 Most important symptoms and effects, both acute and delayed**

See Section 11 for more detailed information on health effects and symptoms.

**4.3 Immediate medical attention and special treatment needed**

Treatment for any adverse effects should be symptomatic. Cephalexin is widely distributed in body fluids and tissues including pleural, pericardial, peritoneal and synovial fluid. It also crosses the placenta. The blood brain barrier is only significantly crossed in the presence of inflammation.

---

**5. FIRE FIGHTING MEASURES**

---

**5.1 Extinguishing media**

Use an extinguishing agent suitable for the surrounding fire.

**5.2 Special hazards arising from the substance or mixture**

Non flammable. May evolve carbon oxides, sulphur oxides, nitrogen oxides and hydrocarbons when heated to decomposition.

**5.3 Advice for firefighters**

Treat as per requirements for surrounding fires. Evacuate area and contact emergency services. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

**5.4 Hazchem code**

None allocated.

---

**6. ACCIDENTAL RELEASE MEASURES**

---

**6.1 Personal precautions, protective equipment and emergency procedures**

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

**6.2 Environmental precautions**

Prevent product from entering drains and waterways.

**6.3 Methods of cleaning up**

If spilt, collect and reuse where possible.

#### **6.4 Reference to other sections**

See Sections 8 and 13 for exposure controls and disposal.

---

## **7. HANDLING AND STORAGE**

---

### **7.1 Precautions for safe handling**

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

### **7.2 Conditions for safe storage, including any incompatibilities**

Store in a cool, dry, well marked area, removed from foodstuffs and other drugs. Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children. Store below 30°C.

### **7.3 Specific end use(s)**

No information provided.

---

## **8. EXPOSURE CONTROLS / PERSONAL PROTECTION**

---

### **8.1 Control parameters**

#### **Exposure standards**

No exposure standards have been entered for this product.

#### **Biological limits**

No biological limit values have been entered for this product.

### **8.2 Exposure controls**

**Engineering controls** Avoid inhalation. Use in well ventilated areas.

#### **PPE**

<b>Eye / Face</b>	Not required under normal conditions of use.
<b>Hands</b>	Individuals with sensitive skin should consider wearing latex gloves.
<b>Body</b>	Not required under normal conditions of use.
<b>Respiratory</b>	Not required under normal conditions of use.



---

## **9. PHYSICAL AND CHEMICAL PROPERTIES**

---

### **9.1 Information on basic physical and chemical properties**

<b>Appearance</b>	ROUND OFF-WHITE TABLETS
<b>Odour</b>	CEPHALEXIN ODOUR
<b>Flammability</b>	NON FLAMMABLE
<b>Flash point</b>	NOT RELEVANT
<b>Boiling point</b>	NOT AVAILABLE
<b>Melting point</b>	NOT AVAILABLE
<b>Evaporation rate</b>	NOT AVAILABLE
<b>pH</b>	NOT AVAILABLE
<b>Vapour density</b>	NOT AVAILABLE
<b>Specific gravity</b>	NOT AVAILABLE
<b>Solubility (water)</b>	SLIGHTLY SOLUBLE
<b>Vapour pressure</b>	NOT AVAILABLE
<b>Upper explosion limit</b>	NOT RELEVANT
<b>Lower explosion limit</b>	NOT RELEVANT
<b>Partition coefficient</b>	NOT AVAILABLE
<b>Autoignition temperature</b>	NOT AVAILABLE
<b>Decomposition temperature</b>	NOT AVAILABLE

**9.1 Information on basic physical and chemical properties**

Viscosity	NOT AVAILABLE
Explosive properties	NOT AVAILABLE
Oxidising properties	NOT AVAILABLE
Odour threshold	NOT AVAILABLE

---

**10. STABILITY AND REACTIVITY**

---

**10.1 Reactivity**

Carefully review all information provided in sections 10.2 to 10.6.

**10.2 Chemical stability**

Stable under recommended conditions of storage.

**10.3 Possibility of hazardous reactions**

Polymerization will not occur.

**10.4 Conditions to avoid**

Avoid contact with incompatible substances.

**10.5 Incompatible materials**

Incompatible with oxidising agents (e.g. hypochlorites).

**10.6 Hazardous decomposition products**

May evolve carbon oxides and hydrocarbons when heated to decomposition.

---

**11. TOXICOLOGICAL INFORMATION**

---

**11.1 Information on toxicological effects**

<b>Acute toxicity</b>	This product is used in veterinary applications. Cephalosporins may cause moderate discomfort if swallowed in large quantities. Use safe work practices to avoid eye contact, prolonged skin contact and ingestion. Refer to medical doctor/specialist for advice regarding adverse side effects.
<b>Skin</b>	Contact may result in irritation, redness and rash.
<b>Eye</b>	Contact may result in irritation, lacrimation, pain, redness and conjunctivitis.
<b>Sensitisation</b>	May cause an allergic skin reaction. This product is not classified as a respiratory sensitiser.
<b>Mutagenicity</b>	Not classified as a mutagen.
<b>Carcinogenicity</b>	Not classified as a carcinogen.
<b>Reproductive</b>	Not classified as a reproductive toxin.
<b>STOT - single exposure</b>	Over exposure may result in irritation of the nose and throat, with coughing.
<b>STOT - repeated exposure</b>	Not classified as causing organ damage from repeated exposure.
<b>Aspiration</b>	Not classified as causing aspiration.

---

**12. ECOLOGICAL INFORMATION**

---

**12.1 Toxicity**

No information provided.

**12.2 Persistence and degradability**

No information provided.

**12.3 Bioaccumulative potential**

No information provided.

**12.4 Mobility in soil**

No information provided.

**12.5 Other adverse effects**

No information provided.

### 13. DISPOSAL CONSIDERATIONS

#### 13.1 Waste treatment methods

**Waste disposal** For small quantities, collect and place in sealable containers. Dispose of, as with other clinical waste, by high temperature incineration (recommended > 1100°C). Burial to landfill may be acceptable, but only at an approved and licensed waste disposal site.

**Legislation** Dispose of in accordance with relevant local legislation.

### 14. TRANSPORT INFORMATION

NOT CLASSIFIED AS A DANGEROUS GOOD BY THE CRITERIA OF THE ADG CODE, IMDG OR IATA

	LAND TRANSPORT (ADG)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
<b>14.1 UN Number</b>	None allocated.	None allocated.	None allocated.
<b>14.2 Proper Shipping Name</b>	None allocated.	None allocated.	None allocated.
<b>14.3 Transport hazard class</b>	None allocated.	None allocated.	None allocated.
<b>14.4 Packing Group</b>	None allocated.	None allocated.	None allocated.

#### 14.5 Environmental hazards

No information provided.

#### 14.6 Special precautions for user

**Hazchem code** None allocated.

### 15. REGULATORY INFORMATION

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

**Poison schedule** Classified as a Schedule 4 (S4) Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).

**Classifications** Safework Australia criteria is based on the Globally Harmonised System (GHS) of Classification and Labelling of Chemicals.

The classifications and phrases listed below are based on the Approved Criteria for Classifying Hazardous Substances [NOHSC: 1008(2004)].

**Hazard codes** Xi Irritant

**Risk phrases** R43 May cause sensitisation by skin contact.

**Safety phrases** S24/25 Avoid contact with skin and eyes.  
S36/37 Wear suitable protective clothing and gloves.  
S46 If swallowed, contact a doctor or Poisons Information Centre immediately and show container or label.

**Inventory listing(s)** **AUSTRALIA: AICS (Australian Inventory of Chemical Substances)**  
All components are listed on AICS, or are exempt.

### 16. OTHER INFORMATION

**Additional information** WORKPLACE CONTROLS AND PRACTICES: Unless a less toxic chemical can be substituted for a hazardous substance, ENGINEERING CONTROLS are the most effective way of reducing exposure. The best protection is to enclose operations and/or provide local exhaust ventilation at the site of chemical release. Isolating operations can also reduce exposure. Using respirators or protective equipment is less effective than the controls mentioned above, but is sometimes necessary.

**PRODUCT NAME CEPHALEXIN ANTIBIOTIC TABLETS - 200MG, 600MG & 1000MG****PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:**

The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

**HEALTH EFFECTS FROM EXPOSURE:**

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

**Abbreviations**

ACGIH	American Conference of Governmental Industrial Hygienists
CAS #	Chemical Abstract Service number - used to uniquely identify chemical compounds
CNS	Central Nervous System
EC No.	EC No - European Community Number
EMS	Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous Goods)
GHS	Globally Harmonized System
GTEPG	Group Text Emergency Procedure Guide
IARC	International Agency for Research on Cancer
LC50	Lethal Concentration, 50% / Median Lethal Concentration
LD50	Lethal Dose, 50% / Median Lethal Dose
mg/m <sup>3</sup>	Milligrams per Cubic Metre
OEL	Occupational Exposure Limit
pH	relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly alkaline).
ppm	Parts Per Million
STEL	Short-Term Exposure Limit
STOT-RE	Specific target organ toxicity (repeated exposure)
STOT-SE	Specific target organ toxicity (single exposure)
SUSMP	Standard for the Uniform Scheduling of Medicines and Poisons
SWA	Safe Work Australia
TLV	Threshold Limit Value
TWA	Time Weighted Average

**Report status**

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

**Prepared by**

Risk Management Technologies  
5 Ventnor Ave, West Perth  
Western Australia 6005  
Phone: +61 8 9322 1711  
Fax: +61 8 9322 1794  
Email: info@rmt.com.au  
Web: www.rmt.com.au

[ End of SDS ]